<H1>Chapter DOI: 10.1007/978-1-60327-829-4_33<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>100</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>98</td></tr><tr><td>BibStructured Count</td><td width="10%">100</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>78</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>4</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>4</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>4</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>4</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_33</td><td>BibArticle</td><td>Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248(3):171&#8211;183.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2796.2000.00742.x>10.1046/j.1365-2796.2000.00742.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_33</td><td>BibArticle</td><td>Bostwick DG, de la RG, Dundore P, Corica FA, Iczkowski KA. Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 2003; 55(3):187&#8211;193.</td><td><a href=http://dx.doi.org/10.1002/pros.10224>10.1002/pros.10224</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_33</td><td>BibArticle</td><td>Theyer G, Kramer G, Assmann I et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66(1):96&#8211;107.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4_33</td><td>BibArticle</td><td>De Marzo AM, Platz EA, Sutcliffe S et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7(4):256&#8211;269.</td><td><a href=http://dx.doi.org/10.1038/nrc2090>10.1038/nrc2090</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_33</td><td>BibArticle</td><td>Steiner G, Gessl A, Kramer G, Schollhammer A, Forster O, Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994; 151(2):480&#8211;484.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_33</td><td>BibArticle</td><td>Steiner GE, Stix U, Handisurya A et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83(8):1131&#8211;1146.</td><td><a href=http://dx.doi.org/10.1097/01.LAB.0000081388.40145.65>10.1097/01.LAB.0000081388.40145.65</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_33</td><td>BibArticle</td><td>Steiner GE, Djavan B, Kramer G et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol 2002; 4(4):171&#8211;177.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_33</td><td>BibArticle</td><td>Steiner GE, Newman ME, Paikl D et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56(3):171&#8211;182.</td><td><a href=http://dx.doi.org/10.1002/pros.10238>10.1002/pros.10238</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_33</td><td>BibArticle</td><td>Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999; 96(12):6879&#8211;6884.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.12.6879>10.1073/pnas.96.12.6879</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_33</td><td>BibArticle</td><td>Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51(5):1202&#8211;1216.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2006.12.011>10.1016/j.eururo.2006.12.011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_33</td><td>BibArticle</td><td>De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155(6):1985&#8211;1992.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)65517-4>10.1016/S0002-9440(10)65517-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_33</td><td>BibArticle</td><td>De Marzo AM, Platz EA, Epstein JI et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006; 30(10):1281&#8211;1291.</td><td><a href=http://dx.doi.org/10.1097/01.pas.0000213289.50660.be>10.1097/01.pas.0000213289.50660.be</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_33</td><td>BibArticle</td><td>Nakayama M, Bennett CJ, Hicks JL et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003; 163(3):923&#8211;933.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)63452-9>10.1016/S0002-9440(10)63452-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_33</td><td>BibArticle</td><td>Sutcliffe S, Zenilman JM, Ghanem KG et al. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 2006; 175(5):1937&#8211;1942.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)00892-X>10.1016/S0022-5347(05)00892-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_33</td><td>BibArticle</td><td>Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13(1):72&#8211;79.</td><td><a href=http://dx.doi.org/10.1097/00001648-200201000-00012>10.1097/00001648-200201000-00012</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_33</td><td>BibArticle</td><td>Taylor ML, Mainous AG, III, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005; 37(7):506&#8211;512.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_33</td><td>BibArticle</td><td>Sutcliffe S, Giovannucci E, Alderete JF et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(5):939&#8211;945.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-05-0781>10.1158/1055-9965.EPI-05-0781</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_33</td><td>BibArticle</td><td>Strickler HD, Goedert JJ. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001; 23(1):144&#8211;151.</td><td><a href=http://dx.doi.org/10.1093/oxfordjournals.epirev.a000781>10.1093/oxfordjournals.epirev.a000781</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_33</td><td>BibArticle</td><td>Urisman A, Molinaro RJ, Fischer N et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006; 2(3):e25.</td><td><a href=http://dx.doi.org/10.1371/journal.ppat.0020025>10.1371/journal.ppat.0020025</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_33</td><td>BibArticle</td><td>Savage PA, Vosseller K, Kang C et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008; 319(5860):215&#8211;220.</td><td><a href=http://dx.doi.org/10.1126/science.1148886>10.1126/science.1148886</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_33</td><td>BibArticle</td><td>Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000; 44(1):49&#8211;54.</td><td><a href=http://dx.doi.org/10.1002/1097-0045(20000615)44:1&lt;49::AID-PROS7&gt;3.0.CO;2-7>10.1002/1097-0045(20000615)44:1&lt;49::AID-PROS7&gt;3.0.CO;2-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_33</td><td>BibArticle</td><td>Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99(2):333&#8211;344.</td><td><a href=http://dx.doi.org/10.1002/jcb.20794>10.1002/jcb.20794</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_33</td><td>BibArticle</td><td>Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004; 92(4):297&#8211;305.</td><td><a href=http://dx.doi.org/10.1016/j.jsbmb.2004.10.016>10.1016/j.jsbmb.2004.10.016</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_33</td><td>BibArticle</td><td>Ho E, Boileau TW, Bray TM. Dietary influences on endocrine- inflammatory interactions in prostate cancer development. Arch Biochem Biophys 2004; 428(1):109&#8211;117.</td><td><a href=http://dx.doi.org/10.1016/j.abb.2004.01.009>10.1016/j.abb.2004.01.009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_33</td><td>BibArticle</td><td>Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005; 135(8):2030S&#8211;2031S.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26_33</td><td>BibArticle</td><td>Heinonen OP, Albanes D, Virtamo J et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90(6):440&#8211;446.</td><td><a href=http://dx.doi.org/10.1093/jnci/90.6.440>10.1093/jnci/90.6.440</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_33</td><td>BibArticle</td><td>Duffield-Lillico AJ, Dalkin BL, Reid ME et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91(7):608&#8211;612.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.2003.04167.x>10.1046/j.1464-410X.2003.04167.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_33</td><td>BibArticle</td><td>Knize MG, Felton JS. Formation and human risk of carcinogenic heterocyclic amines formed from natural precursors in meat. Nutr Rev 2005; 63(5):158&#8211;165.</td><td><a href=http://dx.doi.org/10.1111/j.1753-4887.2005.tb00133.x>10.1111/j.1753-4887.2005.tb00133.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_33</td><td>BibArticle</td><td>Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res 2007; 67(3):1378&#8211;1384.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-1336>10.1158/0008-5472.CAN-06-1336</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_33</td><td>BibArticle</td><td>Leitzmann MF, Platz EA, Stampfer MJ, Willett WC, Giovannucci E. Ejaculation frequency and subsequent risk of prostate cancer. JAMA 2004; 291(13):1578&#8211;1586.</td><td><a href=http://dx.doi.org/10.1001/jama.291.13.1578>10.1001/jama.291.13.1578</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_33</td><td>BibArticle</td><td>Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer &#8211; analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343(2):78&#8211;85.</td><td><a href=http://dx.doi.org/10.1056/NEJM200007133430201>10.1056/NEJM200007133430201</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_33</td><td>BibArticle</td><td>Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997; 33(4):240&#8211;245.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0045(19971201)33:4&lt;240::AID-PROS3&gt;3.0.CO;2-L>10.1002/(SICI)1097-0045(19971201)33:4&lt;240::AID-PROS3&gt;3.0.CO;2-L</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_33</td><td>BibArticle</td><td>Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152(5 Pt 1):1484&#8211;1487.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34_33</td><td>BibArticle</td><td>Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274(5291):1371&#8211;1374.</td><td><a href=http://dx.doi.org/10.1126/science.274.5291.1371>10.1126/science.274.5291.1371</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_33</td><td>BibArticle</td><td>Lindmark F, Zheng SL, Wiklund F et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004; 96(16):1248&#8211;1254.</td><td><a href=http://dx.doi.org/10.1093/jnci/djh227>10.1093/jnci/djh227</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_33</td><td>BibArticle</td><td>Xu J, Zheng SL, Komiya A et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32(2):321&#8211;325.</td><td><a href=http://dx.doi.org/10.1038/ng994>10.1038/ng994</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_33</td><td>BibArticle</td><td>Sun J, Turner A, Xu J, Gronberg H, Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007; 25(3):250&#8211;259.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2006.10.001>10.1016/j.urolonc.2006.10.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_33</td><td>BibArticle</td><td>Castelli JC, Hassel BA, Wood KA et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 1997; 186(6):967&#8211;972.</td><td><a href=http://dx.doi.org/10.1084/jem.186.6.967>10.1084/jem.186.6.967</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_33</td><td>BibArticle</td><td>Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 Spec No 1:R103&#8211;R121.</td><td><a href=http://dx.doi.org/10.1093/hmg/ddh072>10.1093/hmg/ddh072</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_33</td><td>BibArticle</td><td>Bootcov MR, Bauskin AR, Valenzuela SM et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997; 94(21):11514&#8211;11519.</td><td><a href=http://dx.doi.org/10.1073/pnas.94.21.11514>10.1073/pnas.94.21.11514</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_33</td><td>BibArticle</td><td>Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59(4):901&#8211;908.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR42_33</td><td>BibArticle</td><td>Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000; 97(1):109&#8211;114.</td><td><a href=http://dx.doi.org/10.1073/pnas.97.1.109>10.1073/pnas.97.1.109</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_33</td><td>BibArticle</td><td>Paralkar VM, Vail AL, Grasser WA et al. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998; 273(22):13760&#8211;13767.</td><td><a href=http://dx.doi.org/10.1074/jbc.273.22.13760>10.1074/jbc.273.22.13760</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_33</td><td>BibArticle</td><td>Shim M, Eling TE. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 2005; 280(19):18636&#8211;18642.</td><td><a href=http://dx.doi.org/10.1074/jbc.M414613200>10.1074/jbc.M414613200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_33</td><td>BibArticle</td><td>Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999; 65(1):2&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46_33</td><td>BibArticle</td><td>Hayes VM, Severi G, Southey MC et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006; 15(6):1223&#8211;1225.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-06-0063>10.1158/1055-9965.EPI-06-0063</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_33</td><td>BibArticle</td><td>Gough PJ, Greaves DR, Gordon S. A naturally occurring isoform of the human macrophage scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake. J Lipid Res 1998; 39(3):531&#8211;543.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR48_33</td><td>BibArticle</td><td>Peiser L, De Winther MP, Makepeace K et al. The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses. Infect Immun 2002; 70(10):5346&#8211;5354.</td><td><a href=http://dx.doi.org/10.1128/IAI.70.10.5346-5354.2002>10.1128/IAI.70.10.5346-5354.2002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_33</td><td>BibArticle</td><td>Sun J, Hsu FC, Turner AR et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006; 66(7):728&#8211;737.</td><td><a href=http://dx.doi.org/10.1002/pros.20396>10.1002/pros.20396</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_33</td><td>BibArticle</td><td>Alexander RB, Ponniah S, Hasday J, Hebel JR. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 1998; 52(5):744&#8211;749.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(98)00390-2>10.1016/S0090-4295(98)00390-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_33</td><td>BibArticle</td><td>Kim SJ, Uehara H, Karashima T, Mccarty M, Shih N, Fidler IJ. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001; 3(1):33&#8211;42.</td><td><a href=http://dx.doi.org/10.1038/sj.neo.7900124>10.1038/sj.neo.7900124</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_33</td><td>BibArticle</td><td>Zheng SL, ugustsson-Balter K, Chang B et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64(8):2918&#8211;2922.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-3280>10.1158/0008-5472.CAN-03-3280</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_33</td><td>BibArticle</td><td>Sun J, Wiklund F, Zheng SL et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97(7):525&#8211;532.</td><td><a href=http://dx.doi.org/10.1093/jnci/dji070>10.1093/jnci/dji070</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_33</td><td>BibArticle</td><td>Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971; 7:3&#8211;25.</td><td><a href=http://dx.doi.org/10.1111/j.1600-065X.1971.tb00461.x>10.1111/j.1600-065X.1971.tb00461.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR55_33</td><td>BibArticle</td><td>Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442(7101):461&#8211;465.</td><td><a href=http://dx.doi.org/10.1038/nature04808>10.1038/nature04808</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56_33</td><td>BibArticle</td><td>O&#8217;Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85(4):473&#8211;483.</td><td><a href=http://dx.doi.org/10.1054/bjoc.2001.1943>10.1054/bjoc.2001.1943</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57_33</td><td>BibArticle</td><td>Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357(9255):539&#8211;545.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(00)04046-0>10.1016/S0140-6736(00)04046-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58_33</td><td>BibArticle</td><td>Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 1999; 57:16&#8211;21.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR59_33</td><td>BibArticle</td><td>Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000; 164(3 Pt 1):800&#8211;805.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR60_33</td><td>BibArticle</td><td>Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2(10):725&#8211;734.</td><td><a href=http://dx.doi.org/10.1038/nri910>10.1038/nri910</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61_33</td><td>BibArticle</td><td>Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18(1):19&#8211;26.</td><td><a href=http://dx.doi.org/10.1016/j.gde.2008.01.020>10.1016/j.gde.2008.01.020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62_33</td><td>BibArticle</td><td>Luo JL, Tan W, Ricono JM et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446(7136):690&#8211;694.</td><td><a href=http://dx.doi.org/10.1038/nature05656>10.1038/nature05656</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63_33</td><td>BibArticle</td><td>Breen EC. VEGF in biological control. J Cell Biochem 2007; 102(6):1358&#8211;1367.</td><td><a href=http://dx.doi.org/10.1002/jcb.21579>10.1002/jcb.21579</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64_33</td><td>BibArticle</td><td>Aita M, Fasola G, Defferrari C et al. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2008; 68(3):183&#8211;196.</td><td><a href=http://dx.doi.org/10.1016/j.critrevonc.2008.05.002>10.1016/j.critrevonc.2008.05.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65_33</td><td>BibArticle</td><td>Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 2001; 116(1):115&#8211;121.</td><td><a href=http://dx.doi.org/10.1309/1LBM-6X32-JH6W-ENUD>10.1309/1LBM-6X32-JH6W-ENUD</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66_33</td><td>BibArticle</td><td>Ito R, Kitadai Y, Kyo E et al. Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res 1993; 53(17):4102&#8211;4106.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR67_33</td><td>BibArticle</td><td>Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999; 67(1):12&#8211;18.</td><td><a href=http://dx.doi.org/10.1159/000028045>10.1159/000028045</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68_33</td><td>BibArticle</td><td>Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002; 19(3):247&#8211;258.</td><td><a href=http://dx.doi.org/10.1023/A:1015587423262>10.1023/A:1015587423262</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69_33</td><td>BibArticle</td><td>Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12(4):375&#8211;391.</td><td><a href=http://dx.doi.org/10.1016/S1359-6101(01)00016-8>10.1016/S1359-6101(01)00016-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70_33</td><td>BibArticle</td><td>Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917):860&#8211;867.</td><td><a href=http://dx.doi.org/10.1038/nature01322>10.1038/nature01322</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71_33</td><td>BibArticle</td><td>Moore BB, Arenberg DA, Stoy K et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999; 154(5):1503&#8211;1512.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)65404-1>10.1016/S0002-9440(10)65404-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72_33</td><td>BibArticle</td><td>Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 2001; 49(1):30&#8211;37.</td><td><a href=http://dx.doi.org/10.1002/pros.1115>10.1002/pros.1115</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73_33</td><td>BibArticle</td><td>Kovacic P, Jacintho JD. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 2001; 8(7):773&#8211;796.</td><td><a href=http://dx.doi.org/10.2174/0929867013373084>10.2174/0929867013373084</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74_33</td><td>BibArticle</td><td>Sawa T, Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 2006; 14(2):91&#8211;100.</td><td><a href=http://dx.doi.org/10.1016/j.niox.2005.06.005>10.1016/j.niox.2005.06.005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75_33</td><td>BibArticle</td><td>Zidek Z. Role of cytokines in the modulation of nitric oxide production by cyclic AMP. Eur Cytokine Netw 2001; 12(1):22&#8211;32.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR76_33</td><td>BibArticle</td><td>Shen Z, Wu W, Hazen SL. Activated leukocytes oxidatively damage DNA, RNA, and the nucleotide pool through halide-dependent formation of hydroxyl radical. Biochemistry 2000; 39(18):5474&#8211;5482.</td><td><a href=http://dx.doi.org/10.1021/bi992809y>10.1021/bi992809y</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77_33</td><td>BibArticle</td><td>Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30(6):445&#8211;600.</td><td><a href=http://dx.doi.org/10.3109/10409239509083491>10.3109/10409239509083491</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78_33</td><td>BibArticle</td><td>Nelson WG, De Marzo AM, Deweese TL. The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology 2001; 57(4 Suppl 1):39&#8211;45.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(00)00939-0>10.1016/S0090-4295(00)00939-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79_33</td><td>BibArticle</td><td>Bostwick DG, Alexander EE, Singh R et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000; 89(1):123&#8211;134.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20000701)89:1&lt;123::AID-CNCR17&gt;3.0.CO;2-9>10.1002/1097-0142(20000701)89:1&lt;123::AID-CNCR17&gt;3.0.CO;2-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80_33</td><td>BibArticle</td><td>Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997; 89(1):40&#8211;48.</td><td><a href=http://dx.doi.org/10.1093/jnci/89.1.40>10.1093/jnci/89.1.40</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81_33</td><td>BibArticle</td><td>Hirst DG, Robson T. Nitrosative stress in cancer therapy. Front Biosci 2007; 12:3406&#8211;3418.</td><td><a href=http://dx.doi.org/10.2741/2322>10.2741/2322</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82_33</td><td>BibArticle</td><td>Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001; 477(1&#8211;2):7&#8211;21.</td><td><a href=http://dx.doi.org/10.1016/S0027-5107(01)00091-4>10.1016/S0027-5107(01)00091-4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, ArticleTitle, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR83_33</td><td>BibArticle</td><td>Uchida K. A lipid-derived endogenous inducer of COX-2: a bridge between inflammation and oxidative stress. Mol Cells 2008; 25(3):347&#8211;351.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84_33</td><td>BibArticle</td><td>Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 2005; 175(8):5423&#8211;5429.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR85_33</td><td>BibArticle</td><td>Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30(1):3&#8211;21.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR86_33</td><td>BibArticle</td><td>Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190(3):279&#8211;286.</td><td><a href=http://dx.doi.org/10.1002/jcp.10068>10.1002/jcp.10068</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87_33</td><td>BibArticle</td><td>Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31(2 Suppl 7):2&#8211;11.</td><td><a href=http://dx.doi.org/10.1053/j.seminoncol.2004.03.040>10.1053/j.seminoncol.2004.03.040</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88_33</td><td>BibArticle</td><td>Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61(24):8617&#8211;8623.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR89_33</td><td>BibArticle</td><td>Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58(2 Suppl 1):127&#8211;131.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(01)01255-9>10.1016/S0090-4295(01)01255-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90_33</td><td>BibArticle</td><td>Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58(2):362&#8211;366.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR91_33</td><td>BibArticle</td><td>Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004; 10(22):7727&#8211;7737.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-0732>10.1158/1078-0432.CCR-04-0732</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92_33</td><td>BibArticle</td><td>Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 2006; 66(3):257&#8211;265.</td><td><a href=http://dx.doi.org/10.1002/pros.20331>10.1002/pros.20331</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93_33</td><td>BibArticle</td><td>Le NT, Xue M, Castelnoble LA, Jackson CJ. The dual personalities of matrix metalloproteinases in inflammation. Front Biosci 2007; 12:1475&#8211;1487.</td><td><a href=http://dx.doi.org/10.2741/2161>10.2741/2161</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94_33</td><td>BibArticle</td><td>Dieli F, Vermijlen D, Fulfaro F et al. Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67(15):7450&#8211;7457.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-0199>10.1158/0008-5472.CAN-07-0199</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95_33</td><td>BibArticle</td><td>Kottke T, Sanchez-Perez L, Diaz RM et al. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 2007; 67(24):11970&#8211;11979.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-2259>10.1158/0008-5472.CAN-07-2259</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96_33</td><td>BibArticle</td><td>Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007; 42:193&#8211;212.</td><td><a href=http://dx.doi.org/10.1007/1-4020-5688-5_9>10.1007/1-4020-5688-5_9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR97_33</td><td>BibArticle</td><td>Harris RE, Beebe-Donk J, Doss H, Burr DD. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13(4):559&#8211;583.</td><td><a href=http://dx.doi.org/10.3892/or.13.4.559>10.3892/or.13.4.559</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR98_33</td><td>BibArticle</td><td>Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24(18):2723&#8211;2728.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.03.7804>10.1200/JCO.2005.03.7804</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99_33</td><td>BibArticle</td><td>Pruthi RS, Derksen JE, Moore D et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006; 12(7 Pt 1):2172&#8211;2177.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-2067>10.1158/1078-0432.CCR-05-2067</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100_33</td><td>BibArticle</td><td>Sooriakumaran P, Langley SE, Laing RW, Coley HM. COX-2 inhibition: a possible role in the management of prostate cancer? J Chemother 2007; 19(1):21&#8211;32.</td><td><a href=http://dx.doi.org/10.1179/joc.2007.19.1.21>10.1179/joc.2007.19.1.21</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, IssueID, VolumeID, Author_FamilyName_2, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr></table>